The global colorectal cancer molecular diagnostics market is projected to grow significantly, reaching a valuation of USD 5.07 billion by 2032 from USD 2.35 billion in 2022, reflecting a CAGR of 8% over the forecast period from 2022 to 2032. This growth is attributed to the rising global incidence of colorectal cancer and advancements in diagnostic laboratories, which are enabling earlier and more precise cancer detection.
The increasing prevalence of colorectal cancer is a major factor propelling the growth of the molecular diagnostics market. As the cancer burden continues to rise globally, healthcare systems are placing greater emphasis on early detection and precision medicine. Molecular diagnostic tools are emerging as a key enabler of early-stage detection, allowing for more targeted treatment strategies and improved patient outcomes.
In addition, the development of advanced diagnostic laboratories with cutting-edge molecular testing capabilities is creating a favorable environment for market growth. Laboratories are integrating advanced technologies such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid biopsy techniques to ensure faster, more accurate, and less invasive testing. This, in turn, is fostering greater demand for colorectal cancer molecular diagnostics worldwide.
Looking forward, the global colorectal cancer molecular diagnostics market is poised to experience robust growth, with healthcare systems prioritizing early cancer screening programs and personalized cancer treatment. Increased public and private sector investments in oncology research and development will continue to support the production of more efficient molecular diagnostics technologies.
Key Takeaways:
- The global colorectal cancer molecular diagnostics market is projected to grow from USD 2.35 billion in 2022 to USD 5.07 billion by 2032, at a CAGR of 8%.
- Market expansion is driven by the rising prevalence of colorectal cancer and the development of advanced diagnostic laboratories with molecular testing capabilities.
- The adoption of technologies such as PCR, next-generation sequencing (NGS), and liquid biopsy is transforming the early detection and treatment landscape for colorectal cancer.
- Increased R&D investments and government support for early cancer screening programs are expected to further fuel the growth of the market.
As the need for early cancer diagnosis and personalized treatment grows, the adoption of molecular diagnostic tools for colorectal cancer is set to witness a significant uptick. This shift promises to improve survival rates and reduce the economic burden of cancer care across healthcare systems worldwide.
Key Drivers of Market Growth
- Increasing Incidence of Colorectal Cancer: The rising number of colorectal cancer cases globally is a significant factor driving market growth. Approximately 1.4 million new cases are diagnosed each year, highlighting the urgent need for effective diagnostic tools.
- Advancements in Diagnostic Laboratories: The development of diagnostic laboratories and improvements in testing technologies enhance the accuracy and speed of colorectal cancer diagnoses, further stimulating market demand.
- Growing Awareness and Screening Initiatives: Increased public awareness about colorectal cancer and the importance of early detection has led to more individuals undergoing screening tests, contributing to market growth.
- Government Support for Cancer Research: Strong government initiatives aimed at cancer control and research are fostering advancements in molecular diagnostics, which is beneficial for the market.
- Technological Innovations: Continuous advancements in molecular diagnostic technologies, including next-generation sequencing and biomarker identification, are improving diagnostic capabilities and expanding their applications.
Regional Insights
- North America: Expected to hold the largest market share due to advanced healthcare infrastructure, high prevalence rates of colorectal cancer, and significant investments in research and development.
- Asia-Pacific: Anticipated to be the fastest-growing region driven by increasing healthcare expenditures, rising awareness about cancer screening, and improving medical infrastructure.
Market Competition
Some of the key players in the global Colorectal Cancer Molecular Diagnostics market are Dako, Gen Probe (Hologic), Cepheid, Qiagen, Roche Diagnostics, Bayer Healthcare, Abbott Laboratories, Grifols, Guardant Health, Danaher Corporation, Siemens, Beckton Dickinson, Biomérieux Sa, and Sysmex Corporation. Attributed to the presence of such high number of participants, the market is highly competitive.
- In May 2022, Guardant Health launched a shield test that simply draws blood to detect the presence of cancer. This test does not require sedation, dietary changes and is less painful. The shield test detects early signs of colorectal cancer signals in the bloodstream.
Key Companies Profiled
- Dako
- Gen Probe (Hologic)
- Cepheid Qiagen
- Roche Diagnostics
- Bayer Healthcare
- Abbott Laboratories
- Grifols, Danaher Corporation
- Siemens
- Beckton Dickinson
- Biomérieux Sa
- Guardant Health
- Sysmex Corporation
Key Segments Profiled in the Colorectal Cancer Molecular Diagnostics Industry Survey
Colorectal Cancer Molecular Diagnostics Market by Product Type:
- Colorectal Cancer Molecular Diagnostic Instruments
- Colorectal Cancer Molecular Diagnostic Reagents & Kits
- Colorectal Cancer Molecular Diagnostic Services
Colorectal Cancer Molecular Diagnostics Market by Technology:
- PCR-based Colorectal Cancer Molecular Diagnostics
- Sequencing-based Colorectal Cancer Molecular Diagnostics
- Mass Spectrometry-based Colorectal Cancer Molecular Diagnostics
- Transcription Mediated Amplification-based Colorectal Cancer Molecular Diagnostics
- Chips and Microarrays-based Colorectal Cancer Molecular Diagnostics
- Isothermal Nucleic Acid Amplification Technology (INAAT) -based Colorectal Cancer Molecular Diagnostics
Colorectal Cancer Molecular Diagnostics Market by End User:
- Colorectal Cancer Molecular Diagnostics in Hospitals
- Colorectal Cancer Molecular Diagnostics in Ambulatory Surgical Centers
- Colorectal Cancer Molecular Diagnostics in Diagnostic Laboratories
- Colorectal Cancer Molecular Diagnostics in Homecare Settings
Colorectal Cancer Molecular Diagnostics Market by Region:
- North America Colorectal Cancer Molecular Diagnostics Market
- Latin America Colorectal Cancer Molecular Diagnostics Market
- Europe Colorectal Cancer Molecular Diagnostics Market
- Asia Pacific Colorectal Cancer Molecular Diagnostics Market
- Middle East & Africa Colorectal Cancer Molecular Diagnostics Market
Explore FMI’s Related Ongoing Coverage on Healthcare Market Insights Domain:
Non-invasive Brain Stimulation System Market
Non-Hyaluronic Acid Dermal Filler Market
Non-Hospital-Based Point-Of-Care Diagnostic Products Market
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube